Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Curr Opin HIV AIDS. 2010 Jan;5(1):70-7. doi: 10.1097/COH.0b013e328333ad61.
PURPOSE OF REVIEW: Adherence to combination antiretroviral therapy (cART) is one of the most important contributing factors to positive clinical outcomes in patients with HIV, and long-term retention of patients in low-income and middle-income countries is emerging as an important issue in rapidly expanding cART programs. This review presents recent developments in both treatment adherence and retention of patients in low-income and middle-income countries. RECENT FINDINGS: Adherence is among the most modifiable variables in treatment, but there still is no 'gold standard' measurement. Best estimates demonstrate that adherence in resource-limited settings is equal or superior to that in resource-rich settings, possibly due to focused efforts on support groups and community acceptance of adherence behaviors. However, long-term data show that sustained efforts to ensure high cART adherence and evidence of intervention effects are critical, but that resource-intensive interventions are not warranted in settings where cART adherence is high. Furthermore, well conducted evaluation of culturally sensitive interventions to maximize pre-cART and post-cART initiation retention is badly needed in low-income and middle-income settings. SUMMARY: Further research is needed to identify risk factors and to improve adherence and retention among children, adolescents, and adults through use of social networks or emerging technologies for patients at risk for poor adherence.
目的综述:抗逆转录病毒联合治疗(cART)的依从性是影响 HIV 患者临床转归的最重要因素之一,在 cART 项目快速扩展的背景下,如何长期保留中低收入国家的患者成为了一个重要问题。本文综述了中低收入国家患者治疗依从性和保留率方面的最新进展。
最近发现:依从性是治疗中最可改变的变量之一,但仍没有“金标准”的测量方法。最佳估计表明,资源有限环境中的依从性与资源丰富环境中的依从性相当或更高,这可能是由于对支持小组的重视以及对依从性行为的社区认可。然而,长期数据表明,持续努力确保高 cART 依从性和干预效果证据至关重要,但在 cART 依从性高的情况下,不需要资源密集型干预。此外,在中低收入国家,迫切需要开展精心设计的文化敏感性干预措施,以最大限度地提高接受 cART 治疗前和治疗后的保留率。
总结:需要进一步研究,通过使用社交网络或新兴技术,确定风险因素,并提高依从性和保留率,以改善儿童、青少年和成年人的治疗效果。
Curr Opin HIV AIDS. 2010-1
Verh K Acad Geneeskd Belg. 2001
Curr Opin HIV AIDS. 2010-1
Curr Opin HIV AIDS. 2010-1
Int J Environ Res Public Health. 2022-3-25